A Trial to Learn How BAY1817080 Moves Into, Through and Out of the Body and How Safe it is in Healthy Chinese Men
NCT04802343 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39
Last updated 2022-10-19
Summary
Researchers are looking for a better way to treat chronic cough. Before patients with medical conditions can join clinical trials, researchers do trials in healthy participants first to understand how the body acts on the new treatment and learn how safe it is.
In this trial, the researchers will study how much of the trial drug, BAY1817080, gets into the blood in a small number of participants. The trial will include about 39 healthy Chinese male who are aged 18 to 45.
For this trial participants will be divided in 3 groups. Groups 1 and 2 will take either dose 1 or dose 2 of BAY1817080 or placebo 1 time. Participants of groups 3 will take dose 3 of BAY1817080 or placebo one time at the first day and continue to take dose 3 of BAY1817080 twice a day from day 7 to day 16 of the trial. On day 17 they will take only one dose 3 of BAY1817080.
All participants will take BAY1817080 or a placebo as a tablet by mouth. For this trial, the participants in Groups 1 and 2 will stay at the trial site for up to 10 days. The participants in Group 3 will stay at the trial site for up to 26 days. The trial will last up to 4 weeks for the participants in Groups 1 and 2, and 6 weeks for the participants in Group 3.
During the trial, the doctors will take blood and urine samples and check the participants blood pressure, pulse rate and electrocardiogram (ECG). The participants will answer questions about how they are feeling to check their general wellbeing.
Conditions
- Healthy Volunteers
Interventions
- DRUG
-
BAY1817080
Oral, tablet.
- DRUG
-
Oral, tablet.
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- QUADRUPLE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-04-02
- Primary Completion
- 2021-07-19
- Completion
- 2021-10-29
Countries
- China
Study Locations
More Related Trials
-
Dose Extension Study of BIIX 1 XX in Healthy Young Male Volunteers
NCT02198287 ·Status: COMPLETED ·Phase: PHASE1
-
This Study is Done in Healthy Chinese and Japanese Volunteers; it Looks at How BI 690517 is Taken up in the Body and How Well it is Tolerated
NCT03206632 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability and Pharmacokinetics of BI 113608 in Healthy Asian and Caucasian Male Volunteers
NCT01922349 ·Status: COMPLETED ·Phase: PHASE1
-
A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated
NCT05183360 ·Status: TERMINATED ·Phase: PHASE1
-
A Study in Healthy Japanese Men to Test How Different Doses of BI 894416 Are Tolerated
NCT04540874 ·Status: TERMINATED ·Phase: PHASE1
-
The Purpose of This Study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects.
NCT06994286 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics, Immunogenicity, Safety and Tolerability of MEDI3506 in Health Chinese Participants
NCT05070312 ·Status: COMPLETED ·Phase: PHASE1
-
To Assess Safety, Tolerability and Pharmacokinetics of BI 443651 in Healthy Male Volunteers
NCT02706925 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants
NCT04079101 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 60732 in Healthy Male Volunteers
NCT02244203 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single and Multiple Oral BAY1101042 Tablet Doses in Healthy Male Subjects
NCT03252002 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HS-20004 in Healthy Chinese Volunteers
NCT02746302 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male Volunteers
NCT03175211 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of SYHA1805 in Healthy Subjects
NCT04977570 ·Status: UNKNOWN ·Phase: PHASE1
-
Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers
NCT06070857 ·Status: COMPLETED ·Phase: PHASE1
-
A Study in Healthy Men to Test How Well Different Doses of BI 3802876 Are Tolerated
NCT06081530 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 137882 in Healthy Male Volunteers
NCT01348165 ·Status: TERMINATED ·Phase: PHASE1
-
Evaluating the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy Participants
NCT03454126 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability and Pharmacokinetics of BI 1026706 in Healthy Chinese and Japanese Male Volunteers
NCT02652416 ·Status: COMPLETED ·Phase: PHASE1
-
A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated
NCT04978506 ·Status: COMPLETED ·Phase: PHASE1
-
A SAD/MAD Study to Evaluate the Safety, Tolerability, PK and PD of MT2004
NCT04277910 ·Status: COMPLETED ·Phase: PHASE1
-
This Study Tests BI 685509 in Healthy Chinese and Japanese Men; the Study Tests How Different Doses of BI 685509 Are Taken up in the Body and How Well They Are Tolerated
NCT03259464 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability and Pharmacokinetics of AM1476 in Healthy Subjects
NCT04691115 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Pharmacokinetic Study of ARTS-011 in Chinese Healthy Volunteers
NCT06260527 ·Status: COMPLETED ·Phase: PHASE1
-
A Study in Healthy Japanese Men to Test How Different Doses of BI 1569912 Are Taken up by the Body and How Well They Are Tolerated
NCT04958252 ·Status: COMPLETED ·Phase: PHASE1